Effect of mosapride on prednisolone-induced gastric mucosal injury and gastric-emptying disorder in dog.
Effect of mosapride on prednisolone-induced gastric mucosal injury and gastric-emptying disorder in dog.
复制标题
DOI：
10.1292/jvms.12-0066
复制
发表时间：
2012-04
期刊：
影响因子：
--
通讯作者：
A. Tsukamoto;K. Ohno;S. Maeda;K. Nakashima;K. Fukushima;Y. Fujino;M. Hori;H. Tsujimoto
中科院分区：
文献类型：
--
作者：
A. Tsukamoto;K. Ohno;S. Maeda;K. Nakashima;K. Fukushima;Y. Fujino;M. Hori;H. Tsujimoto
既往研究表明，促动力剂莫沙必利在大鼠吲哚美辛胃粘膜损伤模型中具有抗溃疡作用。在这里，我们评估了莫沙必利对泼尼松龙诱导的犬胃粘膜损伤和排空障碍的预防作用。采用交叉研究设计。6只健康比格犬接受泼尼松龙单独给药（2 mg/kg，每日两次[BID]皮下给药）和泼尼松龙与莫沙必利联合给药（1 mg/kg，BID，口服），随后间隔至少6周。在每种治疗中，根据改良Lanza量表对胃粘膜损伤进行内镜评分，并采用（13）C-辛酸呼气试验评估胃排空。还研究了胃肠道不良事件的发生率。莫沙必利与泼尼松龙合用组胃粘膜损伤评分（17.67 ± 6.96）较泼尼松龙单用组（25.50 ± 13.03）显著降低（P<0.05）。与对照组（137 ± 19 min）相比，泼尼松龙治疗组半排空时间（184 ± 45 min）延迟，莫沙必利联合给药可改善胃排空延迟（143 ± 29 min）。此外，与莫沙必利联合给药后，胃肠道不良事件呕吐的发生率降低。除促动力作用外，我们的研究表明莫沙必利在犬中具有抗溃疡作用。莫沙必利联合泼尼松龙可有效减轻泼尼松龙诱导的胃肠道不良事件。
Previous report demonstrated that prokinetic agent mosapride has anti-ulcerogenic action in rat-indomethacin gastric mucosal injury model. Here, we assessed the prophylactic effect of mosapride on gastric mucosal injury and emptying disorder induced by prednisolone in dogs. Crossover study design was employed. Six healthy beagles were administered prednisolone alone (2 mg/kg, twice a day [BID] subcutaneously) and prednisolone with mosapride (1 mg/kg, BID, orally), followed by an interval of at least 6 weeks. In each treatment, gastric mucosal injury was scored endoscopically according to the modified Lanza scale, and gastric emptying was assessed with (13)C-octanoic acid breath test. The incidence of gastrointestinal adverse events was also investigated. Coadministration of mosapride with prednisolone significantly (P<0.05) reduced the gastric mucosal injury score (mean ± SD, 17.67 ± 6.96), compared with that of prednisolone treatment alone (25.50 ± 13.03). Prednisolone treatment delayed the half-emptying time (184 ± 45 min) compared with that of controls (137 ± 19 min), and coadministration of mosapride improved this gastric-emptying delay (143 ± 29 min). Furthermore, the incidence of the gastrointestinal adverse event vomiting became less frequent upon coadministration with mosapride. In addition to its prokinetic action, our study suggests that mosapride has an anti-ulcerogenic action in dogs. The use of mosapride in combination with prednisolone is effective for attenuating prednisolone-induced gastrointestinal adverse events.